… ProQR Announces First Patients Dosed in Phase 2/3 Pivotal … & CAMBRIDGE, Mass., Dec. 16, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … testing,” said Aniz Girach, M.D., Chief Medical Officer of ProQR. “In a previous clinical study, QR-421a appeared to be …
… ProQR spins out all Dystrophic Epidermolysis Bullosa … and CAMBRIDGE, Mass., March 26, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … in a dedicated effort,” said Daniel A. de Boer, CEO at ProQR. “With this transaction we’ve now fully focused our …
… ProQR Announces Presentations at ECFS on Eluforsen for … LEIDEN, The Netherlands, June 04, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … CFF Research Conference. Presentation at ECFS Conference ProQR will deliver a short talk (ePoster) and a poster …
… ProQR Announces Publication on QR-110 for Leber’s Congenital … LEIDEN, the Netherlands, Aug. 01, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … Adamson, Ph.D., senior vice president of ophthalmology for ProQR. “The ongoing clinical trial of QR-110 in patients with …
ProQR scientists report for the first time in the ADAR RNA editing field in vivo proof of target engagement (RNA editing) leading to meaningful changes in biomarkers in NHPs using Axiomer™ RNA Editing OligonucleotidesPreclinical proof of concept for the Company’
ProQR Therapeutics today announced positive results from a planned analysis of its Phase 1/2 Stellar trial of QR-421a in adults with Usher syndrome and non-syndromic retinitis pigmentosa (nsRP) due to USH2A exon 13 mutations.